

UBRELVY[®]
(ubrogepant) tablets | 50mg
100mg

RETHINKING MIGRAINE

**JOIN US FOR AN EXPERT-LED LIVE SPEAKER PROGRAM:
LEADING PATIENT CARE IN THE TREATMENT OF MIGRAINE ATTACKS**

**Tuesday, September 10, 2024
at 6:30 PM CT**

135 Prime
1201 Hewitt Drive
Waco TX



Please RSVP using the link or QR code at left:
<http://www.medforcereg.com/SALG206635>
For questions, contact your AbbVie Representative
Abby Minde Phone: 469.358.6927 Email:
abby.minde@abbvie.com

PRESENTED BY:



Shiraz Yazdani, MD
Pain Medicine
Lubbock Spine Institute
Lubbock TX

INDICATION

UBRELVY[®] (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Drug Interactions: UBRELVY is contraindicated with concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

Hypersensitivity Reactions: UBRELVY is contraindicated in patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product. Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf.

This promotional event is brought to you by AbbVie and is not certified for continuing medical education.

The speaker is a paid consultant presenting on behalf of AbbVie and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is AbbVie's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. AbbVie's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. AbbVie abides by applicable federal and state laws, which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from AbbVie. Please comply with applicable law.